Table 1 Characteristics of included studies. Variables were listed in this systematic review (including:study design, patient demographics, methodology, number of adverse events and length of follow-up). Outcome difference is reported only between adjunctive CHX gel to SRP and SRP alone
Administration | Study | Design | Participants | Methodology | AE | Follow-up (m) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
N (C/T) | Inclusion criteria | SD | age | Description of Gel | CHX Gel Application | |||||
Application at selected sites | Faramarzi M et al. (2017) [26] | P | 68 (34/34) | at least eight teeth with PD 4-8 mm | 2-DM | 30–60 years | XAN-CHX 1.5% CHX gel | one time after 2nd SRP (baseline, 2 week after 1st SRP) | / | 3,6 |
Phogat M et al. (2014) [27] | S | 30 (30/30) | at least 3 nonadjacent interproximal sites with PD 4-8 mm | no | 30–50 years | XAN-CHX 1.5% CHX gel | one time at baseline, 10 days and 20 days | / | 1,3 | |
Jain M et al. (2013) [28] | S | 30 (30/30) | 2 sites located on the same side PD between 5 to 7 mm | no | 30–60 years | XAN-CHX 1.5% CHX gel | one time at baseline | / | 1.5,3,6 | |
Chitsazi MT et al. (2013) [29] | S | 20 (20/20) | one site per quadrant with PD ≥4 mm and BOP (+) | no | mean 46.5 years | XAN-CHX 1.5% CHX gel | one time at baseline | 0 | 1,3 | |
Chauhan AS et al. (2013) [30] | P | 40 (20/20) | at least 8 teeth with PD 4-8 mm | no | 30–65 years | XAN-CHX 1.5% CHX gel | one time at baseline | / | 1,3 | |
Matesanz P et al. (2013) [31] | P (placebo) | 22 (12/10) | at least 16 teeth and at least 3 teeth per quadrant,4–10 pockets with PPD > 4 mm and BOP(+), or at a programmed supportive visit | no | elder than 30 years | XAN-CHX 1.5% CHX gel | one time at baseline | 0 | 1,3,6 | |
Verma A et al. (2012) [32] | S | 46 (46/46) | at least two non-adjacent interproximal sites with PD5-8 mm and BOP(+) | no | 30–65 years | XAN-CHX 1.5% CHX gel | one time 1 month after SRP | / | 1,3 | |
Kranti K et al. (2010) [33] | S (placebo) | 10 (10/10) | at least 4 periodontal pockets with PPD 5-8 mm | yes | 25–65 ears | XAN-CHX 1.5% CHX gel | one time at baseline | / | 3,6 | |
Paolantonio M (2009) [34] | S | 98 (98/98) | at least two teeth with PD ≥5 mm and BOP (+) | no | 24–58 years | XAN-CHX 2.5% CHX gel | one time at baseline | / | 3,6 | |
Gupta R et al. (2008) [35] | S | 30 (30/30) | at least three teeth, (at least one tooth apart), with PPD 5-8 mm and BOP (+) | no | 25–75 years | XAN-CHX 1.5% CHX gel | one time at baseline | / | 1,3 | |
lecic J et al. (2016) [10] | S | 5 (5/5) | at least two bilateral PPD ≥ 5 mm | no | 21–52 years | 0.5% CHX gel | three times within 10 min | / | 1,3 | |
unsal E et al. (1994) 11 | P | 15 (8/7) | at least 3 teeth in each quadrant with 2 sites with PPD ≥ 4 mm and BOP(+) | no | 30–57 years | 1% CHX gel | One time at baseline | / | 3 | |
Oosterwaal PJM et al. (1991) [12] | S (placebo) | 10 (10/10) | at least 4 interdental PPD 7-9 mm in single rooted teeth and BOP(+) | no | 33–62 years | 2% CHX gel | 3 times within 10 min at baseline | / | 1,3,6 | |
Full-mouth application | Fonseca DC et al. (2015) [17] | P | 30 (15/15) | mild to moderate chronic periodontitis, at least 18 natural teeth | yes | 35–60 years | 1% CHX gel | one time at baseline | / | 3,6 |
Santos VR et al. (2013) [18] | P (placebo) | 37 (18/19) | at least 15 teeth, 30% of the sites with concomitant PD and CAL > 4 mm | 2-DM | 37–75 years | 1% CHX gel | 3 times within 10 min at baseline | T:17 C:12 | 3,6,12 | |
swierkot et al. (2009) [19] | P | 18 (9/9) | at least 20 teeth with at least six sites PPD ≥5 mm and BOP(+) | no | 28–63 years | 1% CHX gel | one time at baseline | 0 | 1,2,4,8 | |
Quirynen M et al. (2006) [2] | P | 28 (14/14) | at least 18 teeth, at least 2 multi-rooted and/or 2 single-rooted teeth in the first quadrant, at least 6 sites PPD 6 mm, radiographic bone loss≥25% | no | 30–75 years | 1% CHX gel | three times within 10 min at first sessecion, second session, and 1-week follow-up | / | 2,4,8 | |